wherein R is selected from  $C_1$  to  $C_6$  alkyl amine,  $C_1$  to  $C_6$  dialkyl amine, unsubstituted piperidine, piperazino, pyrrolidino, pyrrolino, morpholino, an amino cyclohexyl derivative or a pharmaceutically acceptable salt thereof.

6. (Once amended) A method of treating asthma comprising administering to a mammal in need thereof an effective amount of a compound of the following formula:

wherein R is selected from C<sub>1</sub> to C<sub>6</sub> alkyl amine, C<sub>1</sub> to C<sub>6</sub> dialkyl amine, unsubstituted piperidino, piperazino, pyrrolino, morpholino, an amino cyclohexyl derivative or a pharmaceutically acceptable salt thereof.

7. (Once amended) A method of treating diarrhea comprising administering to a mammal in need thereof an effective amount of a compound of the following formula:

wherein R is selected from C<sub>1</sub> to C<sub>6</sub> alkyl amine, C<sub>1</sub> to C<sub>6</sub> dialkyl amine, unsubstituted piperidino, piperazino, pyrrolidino, pyrrolino, morpholino, an amino cyclohexyl derivative or a pharmaceutically acceptable salt thereof.

8. (Once amended) A method of regulating at least one of smooth muscle tone, blood vessel growth, and A<sub>2A</sub> antagonist mediated neurotransmitter secretion comprising administering to a mammal in need thereof an effective amount of a compound of the following formula:

wherein R is selected from  $C_1$  to  $C_6$  alkyl amine,  $C_1$  to  $C_6$  dialkyl amine, unsubstituted piperidino, piperazino, pyrrolidino, pyrrolino, morpholino, an amino cyclohexyl derivative or a pharmaceutically acceptable salt thereof.

9. Once amended) A method of treating inflammatory gastrointestinal tract disorders comprising administering to a mammal in need thereof an effective amount of a compound of the following formula:

wherein R is selected from C<sub>1</sub> to C<sub>6</sub> alkyl amine, C<sub>1</sub> to C<sub>6</sub> dialkyl amine, unsubstituted piperidino, piperazino, pyrrolidino, pyrrolino, morpholino, an amino cyclohexyl derivative or a pharmaceutically acceptable salt thereof.

10. (Once amended) A method of treating depression comprising administering to a mammal in need thereof an effective amount of a compound of the following formula:

P2 cont

wherein R is selected from C<sub>1</sub> to C<sub>6</sub> alkyl amine, C<sub>1</sub> to C<sub>6</sub> dialkyl amine, unsubstituted piperidino, piperazino, pyrrolidino, pyrrolino, morpholino, an amine cyclohexyl derivative or a pharmaceutically acceptable salt thereof.

12. (Once amended) A method treating a disease selected from the group consisting of: arthritis, asthma, multiple sclerosis, septic shock, endotoxic shock, gram negative shock, toxic shock, hemorrhagic shock, adult respiratory distress syndrome, organ transplant rejection, cachexia secondary to cancer, osteoporosis, infertility from endometriosis, bacterial meningitis, adverse effects from amphotericin B treatment, adverse effects from interleukin-2 treatment, adverse effects from OKT3 treatment, or adverse effects from GM-CSF treatment comprising administering to a mammal in need thereof, an effective amount of a compound of the following formula:

O HN R  $CH_2CH(CH_3)_2$ 

wherein R is selected from C<sub>1</sub> to C<sub>6</sub> alkyl amine, C<sub>1</sub> to C<sub>6</sub> dialkyl amine, unsubstituted piperidino, piperazino, pyrrolidino, pyrrolino, morpholino, an amino cyclohexyl derivative or a

A2

13. (Once amended) The method of claims 5 or 6 or 8 or 9 or 10 or 12, wherein said compound is incorporated with inert carriers into a tablet and administered orally.

14. (Once amended) The method of claims 5 or 6 or 8 or 9 or 10 or 12, wherein said compound is incorporated with a propellant and a solvent and administered by inhalation of mist.

15. (Once amended) The method of claims 5 or 6 or 8 or 9 or 10 or 12, wherein said compound is incorporated with a pharmaceutically acceptable carrier and injected into said mammal.

19. (Once amended) A method of modulating human mast cell function comprising administering to a patient in need thereof an effective amount of a compound of the following formula:

A3

wherein R is selected from C<sub>1</sub> to C<sub>6</sub> alkyl amine, C<sub>1</sub> to C<sub>6</sub> dialkyl amine, unsubstituted piperidino, piperazino, pyrrolidino, pyrrolino, morpholino, an amino cyclohexyl derivative or a pharmaceutically acceptable salt thereof.

Add the following new claims 22-23 to the application:

22. (New) A compound of the following formula:

A4

wherein R is selected from C<sub>1</sub> to C<sub>6</sub> alkyl amine, C<sub>1</sub> to C<sub>6</sub> dialkyl amine, unsubstituted piperidino, piperazino, pyrrolidino, pyrrolino, morpholino, an amino cyclohexyl derivative or a pharmaceutically acceptable salt thereof

23. (New) A compound having the following formula:

or a pharmaceutically acceptable salt thereof.

## **REMARKS**

Claims 4-10, 12-19 and 22-23 are pending in this application. Claims 1-3, 11, and 20-21 have been cancelled from this application without prejudice. New composition claims 22 and 23 have been added to the application. Claims 5-12 have been amended to convert them into independent claims. Claims 13-16 have been converted into multiple-dependent claims. No new matter has been added to the application by these claims amendments. Marked up claims are attached to this Reply as Appendix A pursuant to 37 CFR 1.121.

By way of review, the Applicants have discovered novel pharmaceutical compounds useful as selective antagonists of the A<sub>2B</sub> adenosine receptor. Furthermore, the present invention relates to novel pharmaceutical compositions useful for treating certain indications including asthma and diarrhea. The present invention also relates to novel methods of treating certain indications including asthma and diarrhea.